Press-release for stocks related to therapeutics

Prices are updated after-hours

tags : Therapeutics crawled date : 2022 - 03 - 15

save search

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Published: 2022-03-15 (Crawled : 22:00) - globenewswire.com
IOVA M | $11.72 -0.68% -0.68% 3.6M

Health Technology

| -5.68% | O: 6.55% H: 0.68% C: 0.45%
therapeutics nasdaq report iot grant granted

Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial Officer as Steve Krognes Transitions to Denali Board of Directors
Published: 2022-03-15 (Crawled : 21:00) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -10.36% | O: 0.82% H: 0.0% C: 0.0%
DNLI | $16.6 -1.31% -1.33% 1.2M

Health Technology

| -41.44% | O: 2.16% H: 2.55% C: 2.31%
therapeutics

Hepatic Encephalopathy Drugs in Development, 2022 - Therapeutics Development & Assessment, Companies Involved, Drug Profiles, Product Development Milestones, Featured News & Press Releases
Published: 2022-03-15 (Crawled : 15:30) - prnewswire.com
TKPHF | $26.52 2.42% 18

Health Technology

| -8.65% | O: -2.86% H: 2.34% C: 2.34%
drug therapeutics companies one milestone

Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022
Published: 2022-03-15 (Crawled : 14:30) - biospace.com/
NBRV | $1.42 1.39% 720K

Health Technology

| 245.84% | O: 2.05% H: 0.24% C: -2.96%
financial results therapeutics report results

Kintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual Meeting
Published: 2022-03-15 (Crawled : 14:30) - biospace.com/
KTRA | $0.1059 2.02% 1.98% 1.7M

Distribution Services

| -67.44% | O: 0.29% H: 3.57% C: 0.65%
america research therapeutics presentation cancer

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
OVID | $3.23 3.86% 3.72% 230K

Health Technology

| -2.81% | O: -2.19% H: 1.92% C: 0.0%
financial results therapeutics report results

Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinson’s and Alzheimer’s Disease at the AD/PD 2022 Conference
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
GANX | $3.15 -0.94% -0.95% 78K

Professional, Scientific, and T...

| -3.64% | O: 9.7% H: 2.76% C: -7.46%
alzheimer pos parkinson conference therapeutics disease positive alzheimer’s alzheimer's disease alzheimer's

NeuroSense Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
NRSN | $1.51 -5.63% -5.96% 270K

| 20.3% | O: 1.5% H: 3.7% C: 3.7%
conference therapeutics axim growth group

Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program
Published: 2022-03-15 (Crawled : 13:30) - globenewswire.com
QLGN | $0.291 -2.15% -2.2% 27K

Health Technology

| -45.45% | O: 5.45% H: 1.98% C: -1.72%
program research therapeutics

Allarity Therapeutics Provides Update on Dovitinib Program
Published: 2022-03-15 (Crawled : 12:30) - globenewswire.com
ALLR | News | $1.53 2.0% 1.96% 760K

n/a

| -99.95% | O: 0.88% H: 8.91% C: 0.87%
program therapeutics

Better Therapeutics Announces Positive Primary Endpoint Data From Pivotal Clinical Trial of BT-001, a Prescription Digital Therapeutic (PDT) for Patients With Uncontrolled Type 2 Diabetes
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
BTTX | $0.009 -65.02% 180K

| -99.77% | O: 9.38% H: 15.12% C: -29.57%
bt-001 pos control trial therapeutics diabetes positive

Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
GLPG | News | $28.9 -1.1% -1.11% 140K

Health Technology

| -52.05% | O: -2.05% H: 1.27% C: 0.79%
financial results therapeutics report results

Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough
Published: 2022-03-15 (Crawled : 12:00) - prnewswire.com
TRVI | $2.68 3.88% 3.73% 180K

Health Technology

| 95.45% | O: 2.27% H: 14.07% C: 8.15%
phase 2 trial therapeutics chronic cough enroll

Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
SAGE | News | $13.03 3.66% 3.53% 1.8M

Health Technology

| -59.07% | O: 1.07% H: 2.93% C: 1.06%
sage-718 phase 2 air parkinson therapeutics presentation disease results

Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU
Published: 2022-03-15 (Crawled : 09:00) - biospace.com/
RLFTF | $1.4 11.45% 1.3K

n/a

| 1900.0% | O: 2.86% H: 0.0% C: -4.72%
RLFTY | $1.4006 733.33% 100

n/a

| -86.36% | O: 0.29% H: 16.31% C: 16.31%
treatment wholly research therapeutics

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
Published: 2022-03-14 (Crawled : 01:00) - biospace.com/
SGTX | $22.47 -2.56% 0.0% 0

Health Technology

| 1655.73% | O: 1.53% H: 4.89% C: -3.01%
financial results therapeutics report results

Curie Therapeutics Appoints Georgette Verdin as Chief People Officer
Published: 2022-03-14 (Crawled : 00:00) - biospace.com/
MSFT F | $404.4 -1.81% -1.94% 21M

Technology Services

| 42.92% | O: -2.7% H: 0.0% C: 0.0%
therapeutics